Introduction {#S1}
============

Pancreatic ductal adenocarcinoma (PDA), the most common type of pancreatic cancer, is one of the most aggressive solid malignancies ([@R1]). With a dismal 5-year survival rate of 5--7%, it is currently the third leading cause of cancer related mortality ([@R2]). In about 95% of cases, PDA initiates with the acquisition of an oncogenic mutation in *KRAS* and progresses through a distinct series of accumulating genetic and morphological alterations marked by tumor cell proliferation, apoptotic evasion, metabolic reprogramming and metastatic dissemination ([@R3]).

Additionally, PDA evolution is characterized by extensive stromal remodeling, with intense desmoplasia and robust immune cell infiltration ([@R4], [@R5]). The immune composition of the PDA microenvironment is sculpted early during transformation, culminating in the accumulation of immunosuppressive cell populations including regulatory T (T~reg~) cells, myeloid-derived suppressor cells (MDSC), and tumor-associated macrophages (TAMs) ([@R6], [@R7], [@R8]). The tumor-protective role of these distinct cell populations in pancreatic neoplasia has been a subject of intense scrutiny. For instance, GM-CSF production by KRas^G12D^-bearing pancreatic tumor cells promotes recruitment of MDSCs to the tumor microenvironment (TME), which in turn promote tumor growth by suppressing immune clearance by CD8^+^ cytotoxic T (Tc) cells ([@R7]). Additionally, TAMs in the PDA microenvironment display a pro-tumorigenic M2-type polarization, which is characterized by expression of immunosuppressive molecules, including IL-10, Arginase 1, TGF-β, and CCl22 and promote a tolerant Th2 immune response ([@R9]). In keeping with the overall immune suppressive nature of the tumor microenvironment, the Th sub-types associated with pancreatic lesions are skewed towards the pro-tumorigenic Th2, T~reg~ and Th17 cells, relative to the Th1 population ([@R6], [@R10], [@R11]). Oncogenic Kras expression in cancer cells directly induces T~reg~ differentiation, which inhibits autoreactive Tc cells, thereby preventing immune clearance of the tumor ([@R12], [@R13], [@R14]). Furthermore, activation of KRas^G12D^ expression specifically upon induction of pancreatitis, a major PDA risk factor, results in expansion of stromal CD4^+^T~reg~ and CD4^+^ Th17 cell populations. Genetic depletion of CD4^+^ T cells in this PDAC model resulted in de-repression of stromal CD8^+^ Tc cells and subsequent attenuation of tumor progression ([@R12]).

Recently, tumor-infiltrating lymphocytic B (TIL-B) cells have been identified as significant positive regulators of PDA initiation and progression ([@R15], [@R16], [@R17]). Robust B cell infiltration is observed in the microenvironment of patient PDA samples. B cell depletion in early and advanced stage mouse models of pancreatic cancer was found to significantly attenuate tumor establishment and progression ([@R17]). Furthermore, in the *LSL-Kras*^*G12D*^*; p48*^*Cre*^ (*KC*) mouse model of pancreatic intra-epithelial neoplasia (PanIN), we have previously uncovered a crucial role for a specialized B cell-subset in PanIN evolution ([@R16]). The PanIN microenvironment is enriched in IL-10 and IL-35 producing immunosuppressive CD1d^hi^CD5^+^ B regulatory (B~reg~) cells, loss of which severely attenuates PanIN growth. We identified IL-35 as a prominent downstream effector of CD1d^hi^CD5^+^ B~reg~ function in pancreatic tumorigenesis by directly stimulating tumor cell proliferation ([@R16]). While the stromal-derived chemokine CXCL13 was found to potentiate B cell recruitment to the PanIN microenvironment ([@R16]), the molecular mechanisms regulating their further differentiation and function in the PanIN stroma remain unknown.

In light of these observations, we sought to dissect the molecular mechanisms regulating CD1d^hi^CD5^+^ B~reg~ expansion in the PanIN milieu. As a cytoplasmic non-receptor tyrosine kinase, the Bruton's Tyrosine Kinase (BTK) enzyme plays a central role in regulating B cell development and function, serving as a downstream signal transducer for a variety of cytokine and chemokine receptors, antigen receptors and integrins ([@R18]). BTK-mediated signaling is in turn transmitted through several prominent downstream effectors including phosphoinositol-3 kinase (PI3K)-AKT, phospholipase-C (PLC), protein kinase C and nuclear factor κB (NF-κB) ([@R19], [@R20]). For instance, BTK activation upon antigen-mediated B cell receptor (BCR) engagement promotes B cell survival, proliferation and antibody production through PLCγ2 and subsequent NF-κB activation ([@R21]). Additionally, BTK is also a mediator of the TLR signaling pathway, wherein in complex with Myd88 it activates the NF-κB transcription factor and subsequently regulates expression of pro- and anti-inflammatory cytokines ([@R22], [@R23]).

While BTK-mediated regulation of the immunosupressive cytokine IL-10 has been described in macrophages and B cells ([@R24], [@R25]), its role in regulating B~reg~ biology remains unexplored. In the current study, we have uncovered a role for BTK as a critical regulator of CD1d^hi^CD5^+^ B~reg~ differentiation and immunosuppressive function. Furthermore, our findings point to a potential therapeutic strategy for targeting pancreatic cancer.

Results and discussion {#S2}
======================

We initiated our study by first investigating whether BTK activity is necessary for CD1d^hi^CD5^+^ B~reg~ evolution. To this end, we assessed the effect of the BTK inhibitor tirabrutinib on naïve murine splenic B cells treated with IL-6, IL-1β and α-CD40 antibody. These inflammatory signals, which are also enriched in the PanIN stroma ([@R26]), have been shown to induce differentiation of mouse splenic B~reg~ cells ([@R27]). Furthermore, both CD40 and the IL-6 receptor activate BTK ([@R28], [@R29]), as do the downstream effectors of the IL-1 receptor Myd88 and IRAK-1 ([@R30]), suggesting a role for BTK in B~reg~ differentiation induced by these pathways.

As illustrated in [Fig 1a, b](#F1){ref-type="fig"} and [Supplementary Figure S1a](#SD1){ref-type="supplementary-material"}, inflammatory stimulation of splenic B cells from naïve mice upregulated BTK activation as measured by pBTK (Y223) expression ([@R19]). Cytokine treatment of B cells did not alter total BTK protein levels ([Supplementary Fig. S1a](#SD1){ref-type="supplementary-material"}). This increase was accompanied by an expansion of the CD1d^hi^CD5^+^ B~reg~ population ([Fig. 1c, 1d](#F1){ref-type="fig"}). Significantly, inhibition of BTK activation by tirabrutinib ([Fig. 1a, 1b](#F1){ref-type="fig"}, [Supplementary Fig. S1a](#SD1){ref-type="supplementary-material"}) attenuated cytokine-induced CD1d^hi^CD5^+^ B~reg~ differentiation ([Fig. 1c, 1d](#F1){ref-type="fig"}). Furthermore, tirabrutinib markedly downregulated expression of both CD1d^hi^CD5^+^ B~reg~ functional markers, IL-10 ([Fig. 1e](#F1){ref-type="fig"}, [Supplementary Fig. S1b](#SD1){ref-type="supplementary-material"}) and IL-35 (heterodimer of Ebi3 and p35, encoded by the *Ebi3* and *IL12A* genes, respectively) ([Fig. 1f, 1g](#F1){ref-type="fig"}), which are critical mediators of CD1d^hi^CD5^+^ B~reg~ immunosuppressive function. Collectively, our results directly implicate the BTK signaling pathway in promoting CD1d^hi^CD5^+^ B~reg~ differentiation and production of the immunomodulatory cytokines IL-10 and IL-35.

To ascertain whether CD1d^hi^CD5^+^ B~reg~ evolution in pancreatic neoplasia is also regulated by BTK signaling, we first assessed the status of BTK activation in PanIN-associated B~reg~ cells. Immunostaining of tissue sections from LSL-Kras^G12D^; p48-Cre (*KC)* ([@R31]) mice pancreata displayed co-localisation of pBTK (Y223) with IL-10 producing CD19^+^ B cells ([Fig. 2a](#F2){ref-type="fig"}, [Supplementary Fig. S2a](#SD1){ref-type="supplementary-material"}). We did not detect significant differences in overall BTK levels between regulatory and non-regulatory B cell populations in the *KC* pancreatic stroma ([Supplementary Fig. S2a](#SD1){ref-type="supplementary-material"}). Furthermore, flow cytometric analysis of the pancreata of *KC* mice ([Fig. 2b](#F2){ref-type="fig"}, [Supplementary Fig. S2b](#SD1){ref-type="supplementary-material"}) as well as orthotopically implanted Kras^G12D^-PanIN lesions ([@R7]) ([Supplementary Fig. S2c](#SD1){ref-type="supplementary-material"}) revealed the expression of activated pBTK (Y223) specifically in PanIN-associated CD1d^hi^CD5^+^ B~reg~ cells. Plausible mechanisms for this observed BTK activation in stromal B cells include CD40, TLR4 and IL-6 signaling, all of which are enriched in the PanIN stroma ([@R28], [@R29], [@R30], [@R32], [@R33], [@R34]) and shown to regulate BTK activity. Interestingly, the TLR4 downstream effectors Myd88 and IRAK4 that mediate BTK phosphorylation are also interacting partners of the IL-1β receptor IL1R1. Since IL-1β is reported to be produced in pancreatic tumors ([@R26]), we sought to assess the contribution of IL-1β to BTK activation in PanIN-stromal B cells. Orthotopically implanted Kras^G12D^-PanIN lesions were significantly enriched in IL-1β protein, relative to sham injections ([Supplementary Fig. S2d](#SD1){ref-type="supplementary-material"}). As outlined in [Fig. 2c](#F2){ref-type="fig"}, Kras^G12D^-PanIN lesions implanted in wild type or *IL1R1−/−* mouse pancreas were analysed for BTK (Y223) phosphorylation in PanIN-associated B cells. *IL1R1−/−* stromal B cells displayed significantly lower pBTK (Y223) levels relative to wild type control ([Fig. 2d](#F2){ref-type="fig"}), indicating that IL-1 signaling in the PanIN TME contributes to BTK activation in stromal B cells.

We next sought to determine the functional significance of BTK activity in PanIN-associated CD1d^hi^CD5^+^ B~reg~ cells. Wild type mice bearing orthotopically implanted Kras^G12D^-PanIN lesions were treated with tirabrutinib as outlined ([Fig. 3a](#F3){ref-type="fig"}). Tirabrutinib inhibited BTK activation as measured by pBTK (Y223) staining in the PanIN stroma ([Fig. 3b](#F3){ref-type="fig"}) and more specifically in infiltrating B cells ([Fig. 3c](#F3){ref-type="fig"}, [Supplementary Fig. S3a](#SD1){ref-type="supplementary-material"}). Considering the crucial role of BTK in B cell proliferation and survival, we analyzed the effect of tirabrutinib treatment on both CD1d^hi^CD5^+^ B~reg~ cells and the overall tumor-infiltrating B cell population. BTK inhibition did not significantly alter the total CD19^+^ B cell fraction in the tumor stroma after 2 weeks of tirabrutinib treatment ([Fig. 3d](#F3){ref-type="fig"}; [Supplementary Fig. S3b, S3c](#SD1){ref-type="supplementary-material"}). On the other hand, the CD1d^hi^CD5^+^ B~reg~ subset displayed remarkable sensitivity to BTK inhibition, with a significant decrease in the stromal population within 2 weeks of treatment, relative to the vehicle control ([Fig. 3e](#F3){ref-type="fig"}; [Supplementary Fig. S3d, S3e](#SD1){ref-type="supplementary-material"}). Prolonged tirabrutinib treatment for 4 weeks induced a small but significant decrease in stromal CD19^+^ B cells ([Fig. 3d](#F3){ref-type="fig"}; [Supplementary Fig. S3b](#SD1){ref-type="supplementary-material"}) while markedly decreasing the CD1d^hi^CD5^+^ B~reg~ population, relative to vehicle control ([Fig. 3e](#F3){ref-type="fig"}; [Supplementary Fig. S3d](#SD1){ref-type="supplementary-material"}). CD1d^hi^CD5^+^ B~reg~ cells primarily mediate immunosupression by inhibiting Tc cell activation ([@R35]). Consistent with this, CD1d^hi^CD5^+^ B~reg~ depletion upon BTK inhibition was accompanied by a significant increase in the IFNγ^+^CD8^+^ Tc cell population ([Fig. 3f](#F3){ref-type="fig"}; [Supplementary Fig. S3f](#SD1){ref-type="supplementary-material"}) without altering the overall CD8^+^ Tc cell proportion ([Supplementary Fig. S3g](#SD1){ref-type="supplementary-material"}), further implicating BTK in the immunomodulatory function of CD1d^hi^CD5^+^ B~reg~.

The physiologic importance of CD1d^hi^CD5^+^ B~reg~ attenuation upon BTK inhibition is highlighted by the reduced growth of the PanIN lesions ([Fig. 4a and 4b](#F4){ref-type="fig"}). Tirabrutinib significantly inhibited proliferation of the tumor cells, relative to the vehicle control ([Fig. 4c and 4d](#F4){ref-type="fig"}), as measured by immunohistochemical staining of the proliferation marker phospho-Histone H3 staining in the Kras^G12D^-transformed epithelia. We did not detect induction of apoptosis upon tirabrutinib treatment, as assessed by cleaved caspase 3 staining (data not shown). This is consistent with our previously reported observation that the attenuation of PanIN growth in the absence of stromal CD1d^hi^CD5^+^ B~reg~ cells is due to inhibition of epithelial proliferation ([@R16]). Taken together our observations implicate BTK in the development of pancreatic neoplasia through the regulation of CD1d^hi^CD5^+^ B~reg~ differentiation in the PanIN microenvironment.

Given the critical role of immunomodulation in promoting pancreatic tumorigenesis, understanding the molecular mechanisms mediating this process is essential for developing effective immunotherapeutic strategies for combating the disease. Initial efforts with checkpoint inhibitors such as α-CTLA-4 and α-PD-1 which show promise in other cancers have proved ineffective for pancreatic cancer ([@R36]), underscoring the need to identify and therapeutically explore additional targets.

In our pre-clinical model of pancreatic neoplasia, the observed decrease in stromal CD1d^hi^CD5^+^ B~reg~ population upon BTK inhibition is accompanied by significant attenuation of Kras^G12D^-epithelial proliferation and PanIN growth. Additionally, BTK inhibition also led to a small but significant engagement of the Tc cell response, as measured by increased IFNγ production in CD8^+^ T cells. Our results thus indicate that combining the cytostatic effect of BTK inhibitors with checkpoint-directed immunotherapy, which can further enhance the Tc cell response, may provide an effective multipronged approach for PDA therapy. BTK inhibitors are already approved as monotherapy for B cell malignancies ([@R37]), while clinical trials assessing the efficacy of BTK inhibitors in combination with anti-PD-1 immunotherapy are currently underway (e.g.-[clinicaltrials.gov](clinicaltrials.gov); NCT02362048).

In addition to pancreatic cancer, regulatory B cells have also been found to promote other tumor types including melanoma, mammary and squamous cell carcinoma ([@R38]). As such, understanding the molecular pathways regulating their development and function is of great importance. Unlike regulatory T cells, regulatory B lymphocytes are a heterogeneous population without well-defined precursors or developmental lineage ([@R35]). Instead, these cells exhibit great plasticity, differentiating in response to extracellular inflammatory cues from their microenvironment. While some of these inflammatory signals have been described, the downstream molecular pathways regulating the process remain to be elucidated. We have identified BTK as a direct cell-intrinsic regulator of CD1d^hi^CD5^+^ B~reg~ differentiation. BTK inhibition downregulates expression of the cytokines IL-10 and IL-35, expanding its potential role to additional immunosuppressive B cell subsets such as the i35-B~reg~ population as well as in various autoimmune conditions ([@R39], [@R40]). Further characterization of this pathway would not only enable a deeper understanding of this hitherto elusive B cell sub-population but also expand our repertoire of potential therapeutic candidates for immunotherapy.

Supplementary Material {#SM1}
======================

###### 

Fig. S1 a Western blot analysis of protein lysates from mouse splenic B cells treated as indicated. Antibodies used: Phospho-BTK (Tyr 223) (5082S, Cell Signaling Technologies, Danvers, MA) and BTK (8547S, Cell Signaling Technologies), β-actin (8457S, Cell Signaling Technologies). b Representative intracellular flow cytometric analysis of IL-10 expression in murine splenic B cells, treated as indicated. After gating on the CD19+ population, cells were analysed for IL-10. Also shown is isotype control for IL-10 staining.

Fig. S2 a Representative immunofluorescent staining of 2 month old KC mice (N=6) (31) pancreata to detect co-localisation of pBTK (Y223) with IL-10 and B cell marker CD19. Mice pancreata were fixed, processed and stained as described previously (7). Antibody used was BTK (1:100, ab137503, Abcam, Cambridge, UK), CD19 (1:50, 550284, BD Biosciences, San Jose, CA, USA) and IL-10 (1:50, sc-365858, Santa Cruz Biotechnology, Dallas, TX, USA). Slides were examined and imaged on a Nikon Eclipse Ti2 microscope. b Gating strategy for intracellular flow cytometric analysis of pBTK (Y223) expression in B cells from KC mice pancreata. Single cell suspension from pancreatic tissue was prepared as described previously (7) and stained with the following antibodies: CD45 (2D1, 368521, Biolegend); CD19 (6D5, \#115506, Biolegend), CD1d (1B1, 123509, Biolegend), CD5 (53--7.3, 100621, Biolegend), pBTK (Y223) (N35--86, 564848, BD). After gating on the CD45+ and CD19+ population, cells were analysed for pBTK (Y223) expression in CD1dhiCD5+ Breg. c Representative intracellular flow cytometric analysis of pBTK (Y223) in B cells from 2 week-old KrasG12D-PDEC orthotopic lesions implanted (N=4), as described before (7). Also shown are isotype controls for pBTK (Y223) staining. Graph represents quantification of FACS analysis, indicating percentage of CD1dhiCD5+ Breg cells expressing pBTK (Y223) in KrasG12D-PDEC orthotopic lesions (N=4). Error bars indicate SD. P-value calculated using Student t test (two tailed, unpaired). \*, P≤0.05. d Level of IL-1β protein in KrasG12D orthotopic lesions (2 weeks old, N=4), as assessed by ELISA. PanIN lesions were harvested, minced with sterile razor blades and incubated in 500 μl of complete media for 12 h. Supernatant was analysed using the mouse IL-1 beta/IL-1F2 Duoset ELISA kit (DY-401-05, R&D Systems, Minneapolis, MN) as per manufacturer instructions. Error bars indicate SD. P-value calculated using Student t test (two tailed, unpaired). \*\*, P≤0.01.

Fig. S3 a Representative intracellular flow cytometric analysis of pBTK (Y223) in B cells from KrasG12D-PDEC orthotopic lesions treated with vehicle or tirabrutinib for 2 weeks. b Representative flow cytometric analysis of CD19+ B cells in KrasG12D-PDEC orthotopic lesions treated with vehicle or tirabrutinib for 2 or 4 weeks. c Graph represents number of CD19+ B cells in KrasG12D-PDEC orthotopic lesions treated with vehicle or tirabrutinib for 2 weeks. Error bars indicate SD. P-value calculated using Student t test (two tailed, unpaired). N.S., P\>0.05. d Representative flow cytometric analysis of CD1dhiCD5+ B cells in KrasG12D-PDEC orthotopic lesions treated with vehicle or tirabrutinib for 2 and 4 weeks. Cells gated on CD19 and CD1d markers were analysed for CD5 expression. e Graph represents number of CD1dhiCD5+ B cells in KrasG12D-PDEC orthotopic lesions treated with vehicle or tirabrutinib for 2 weeks. Error bars indicate SD. P-value calculated using Student t test (two tailed, unpaired). \*, P≤0.05 f Representative intracellular flow cytometric analysis of IFNγ+ CD8+ cytotoxic T cells in KrasG12D-PDEC orthotopic lesions treated with vehicle or tirabrutinib for 2 weeks. Cells gated on CD45, CD3 and CD8 markers were analysed for IFNγ expression. g Representative flow cytometric analysis of CD8+ cytotoxic T cells in KrasG12D-PDEC orthotopic lesions treated with vehicle or tirabrutinib for 2 weeks. Cells gated on CD45 and CD3 were analysed for CD8 surface marker. Graph represents quantification of FACS analysis, indicating CD8+ cytotoxic T cells as a percentage of total CD3+ T cells. Error bars indicate SD. P-value calculated using Student t test (two tailed, unpaired). N.S., P\>0.05.
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![BTK activity directly regulates CD1D^hi^CD5^+^ Breg development and function. Wild type C57BL/6 (8 weeks old, Charles River Laboratories, Wilmington, MA, USA) mice spleens were mechanically disrupted, suspended in 1%FBS/PBS, filtered through a 70-μm strainer (352350, Corning Falcon), and treated with RBC lysis buffer (00--4300-54, Thermo Fisher Scientific, Waltham, MA, USA). B cells were isolated from this single-cell suspension using CD45R (B220)-linked MACS beads (130--049-501, Miltenyi, Bergisch Gladbach, Germany) and MS columns (130--042-201, Miltenyi) as per manufacturer instructions. B cell enrichment was confirmed by flow cytometry using FITC-CD19 (6D5, 115506, Biolegend, San Diego, CA, USA) on FACScalibur (BD Biosciences, San Jose, CA, USA) and purified cells were cultured in DMEM (Gibco, Gaithesburg, MD, USA) supplemented with 10% (v/v) FBS (Gibco) and 1% (v/v) penicillin and streptomycin (Gibco). Immediately post isolation, B cells were treated with anti-CD40 (10 ug/ml; FGK4.5/FGK45, BE0016--2, BioXCell, West Lebanon, NH, USA), IL-1β (20 ng/ml; 401-ML-005, R&D Systems, Minneapolis, MN, USA), IL-6 (20 ng/ml; 406-ML-005, R&D Systems) and tirabrutinib (5 μM, Gilead Sciences, Foster City, CA, USA) for 48 hours. **a** Representative population distribution of pBTK (Y223) expressing CD19^+^ B cells, treated as indicated for 48h and analysed by flow cytometry on LSR II (BD Biosciences). Data were analysed using FlowJo (v10) software. Following antibodies were used as per product datasheet for flow cytometry: CD19 (6D5, \#115506, Biolegend); pBTK (Y223) (N35--86, 564848, BD Biosciences). **b** Quantification of data in **a**, graph depicts median fluorescence intensity (MFI) of pBTK (Y223) staining in isolated wild type splenic CD19^+^ B cells treated as indicated for 48 h (N=3). Error bars represent SD, *P*-value calculated using Student *t* test (two-tailed, unpaired). \*\*, P≤0.01. Data representative of three independent experiments. **c** Representative flow cytometry analysis of isolated wild type splenic CD19^+^ B cells treated as indicated for 48 h. Cells gated on CD19^+^ were analysed for CD1d and CD5 expression. Following antibodies were used as per product datasheet for flow cytometry: CD19 (6D5, \#115506, Biolegend), CD1d (1B1, 123509, Biolegend) and CD5 (53--7.3, 100621, Biolegend). **d** Graph depicts quantification of associated flow cytometry data in **c**, collected on LSR II (BD Biosciences) and analysed using FlowJO (v10) software, indicating CD1d^hi^CD5^+^ cells as percentage of CD19^+^ B cells (N=3). Error bars represent SD; *P*-value calculated using Student *t* test (two-tailed, unpaired). \*\*, P≤0.01; \*\*\*, P≤0.001. Data representative of three independent experiments. **e** Quantification of flow cytometric analysis of CD19^+^ B cells treated as indicated, graph depicts IL-10^+^ cells as percentage of CD19^+^ B cells, N=3. Following antibodies were used as per product datasheet for flow cytometry: CD19 (6D5, \#115506, Biolegend) and IL-10 (JES5--16E3, 505009, Biolegend). Error bars represent SD; P value calculated using Student *t* test (two-tailed, unpaired); \*, P≤0.05; \*\*, P≤0.01. Data representative of three independent experiments. **f, g** Graph depicting levels of *Ebi3* (**f**) and *IL12A* (**g**) mRNA expression in wild type splenic B cells, treated as indicated for 48 h and measured by qRT-PCR (N=3). RNA was isolated using an RNeasy mini kit (74104, QIAGEN, Venlo, Netherlands) and reverse transcribed using QuantiTect reverse transcription kit (205311, QIAGEN). USB HotStart-IT SYBR Green qPCR Master Mix (75762, Affymetrix, Santa Clara, CA, USA) was used for amplification. Expression was normalized to GAPDH. Fold expression was determined using the 2^-ΔΔCT^ method. Error bars represent SD; *P*-value calculated using Student *t* test (two tailed, unpaired). \*, P≤0.05. Data representative of three independent experiments. All animal care and procedures were approved by the Institutional Animal Care and Use Committee at NYU School of Medicine.](nihms-1516906-f0001){#F1}

![BTK is activated in PanIN-associated regulatory B cells. **a** Representative immunofluorescent staining of 2 month old *KC* mice (N=6) ([@R31]) pancreata to detect co-localisation of pBTK (Y223) with IL-10 and B cell marker CD19. Mice pancreata were fixed, processed and stained as described previously ([@R7]). Antibodies used were pBTK (Y223) (1:200, 109336, LSBio, Seattle, WA, USA), CD19 (1:50, 550284, BD Biosciences, San Jose, CA, USA) and IL-10 (1:50, sc-365858, Santa Cruz Biotechnology, Dallas, TX, USA). Slides were examined and imaged on a Nikon Eclipse Ti2 microscope. Scale bar, 100 μm. **b** Representative intracellular flow cytometric analysis of pBTK (Y223) in B cells from pancreata of *KC* mice ([@R31]), as described previously ([@R7]). Single cell suspension from pancreatic tissue was prepared as described previously ([@R7]) and stained with the following antibodies for flow cytometry analysis: CD45 (2D1, 368521, Biolegend); CD19 (6D5, \#115506, Biolegend), CD1d (1B1, 123509, Biolegend), CD5 (53--7.3, 100621, Biolegend), pBTK (Y223) (N35--86, 564848, BD). After gating on the CD45^+^ and CD19^+^ population, cells were analysed for pBTK (Y223) expression in CD1d^hi^CD5^+^ B~regs~. Also shown are isotype controls for pBTK (Y223) staining. Graph represents quantification of FACS analysis, indicating percentage of CD1d^hi^CD5^+^ B~reg~ cells expressing pBTK (Y223) in *KC* mice (2--3 mo old, N=5). Error bars indicate SD. *P*-value calculated using Student *t* test (two tailed, unpaired). \*\*, P≤0.01. **c** Experimental schematic for pBTK analysis of Kras^G12D^-PDEC orthotopic lesions in wild type or *IL1R1−/−* mice. **d** Western blot analysis of pBTK expression in PanIN-associated wild type or *IL1R1−/−* B cells. Total B cells were isolated from 2 week old pancreatic orthotopic lesions implanted in wild type (C57BL/6J, Jackson Laboratory, Bar Harbor, ME, USA) or *IL1R1−/−* mice (B6.129S7-Il1r1tm1Imx/J, Jackson Laboratory) (N=5) using CD45R (B220)-linked MACS beads (130--049-501, Miltenyi) and MS columns (130--042-201, Miltenyi) as per manufacturer instructions. Isolated cells were lysed in sample buffer and analysed by immunoblotting on a LiCor Odyssey imager using the following antibodies: Phospho-BTK (Tyr 223) (5082S, Cell Signaling Technologies, Danvers, MA) and BTK (8547S, Cell Signaling Technologies).](nihms-1516906-f0002){#F2}

![BTK inhibition downregulates CD1d^hi^CD5^+^ regulatory B cells in PanIN stroma. **a** Schema for tirabrutinib administration in PanIN-bearing mice (10mg/kg; QD; administered orally), initiated 1 week post Kras^G12D^-PDEC orthotopic implantation. Briefly, 10^6^ Kras^G12D^ PDECs were injected in the pancreas of 8 weeks old, female C57BL/6 mice (Charles River). PanIN-bearing mice were randomly assigned to control and experimental groups for subsequent drug treatment Sample sizes for experiments were determined without formal power calculation. Investigators were not blinded to group allocation or outcome assessment. **b** Representative immunohistochemical detection of stromal pBTK (Y223) in Kras^G12D^-PDEC orthotopic lesions treated with vehicle or tirabrutinib for 2 weeks. Mice pancreata were fixed, processed and stained by immunohistochemistry (IHC) as decribed previously ([@R7]). Antibodies used were pBTK (Y223) (1:200, 109336, LSBio, Seattle, WA, USA). Slides were examined and imaged on a Nikon Eclipse 80i microscope. Scale bar, 200 μm. **c** Quantification of intracellular flow cytometric analysis of pBTK (Y223) expression in CD19^+^ B cells from Kras^G12D^-PDEC orthotopic lesions treated with vehicle or tirabrutinib for 2 weeks (N=7). Error bars indicate SD; *P*-values determined by the Student *t* test (two-tailed, unpaired); \*\*\*, P\<0.001. **d** Quantification of flow cytometric analysis of CD19^+^ B cells from vehicle or tirabrutinib treated Kras^G12D^-PDEC orthotopic lesions for 2 and 4 weeks. (N=7, 2 weeks treatment cohort; N=8, 4 weeks treatment cohort). Error bars indicate SD; *P*-values determined by the Student *t* test (two-tailed, unpaired). \*, P≤0.05. Data representative of two independent experiments. **e** Quantification of flow cytometric analysis of CD1d^hi^CD5^+^ Breg cells from vehicle or tirabrutinib treated Kras^G12D^-PDEC orthotopic lesions for 2 and 4 weeks. Cells gated on CD19^+^CD1d^hi^ were analysed for CD5 expression, graph represents CD5^+^ cells as percentage of CD19^+^CD1d^hi^ B cells. (N=7, 2 weeks treatment cohort; N=8, 4 weeks treatment cohort). Error bars indicate SD; *P*-values determined by the Student *t* test (two-tailed, unpaired). \*\*, P≤0.01. Data representative of two independent experiments. **f** Quantification of intracellular flow cytometric analysis of IFNγ expression in CD8^+^ T cells isolated from Kras^G12D^-PDEC orthotopic lesions treated with vehicle or tirabrutinib for 2 weeks (N=6). Cells gated on CD45^+^CD3^+^CD8^+^ were analysed for IFNγ expression. Following antibodies were used as per product datasheet for flow cytometry: CD45 (2D1, 368521, Biolegend); CD3 (145--2C11, 100327, Biolegend); CD8 (53--6.7, 100713, Biolegend), IFNγ (XMG1.2, 11--7311-82, Thermo Fisher Scientific). Error bars indicate SD; *P*-values determined by the Student *t* test (two-tailed, unpaired). \*\*, P≤0.01.](nihms-1516906-f0003){#F3}

![Tirabrutinib treatment inhibits proliferation and restricts growth of Kras^G12D^-PanIN lesions. **a** Immunohistochemical detection of CK8 in sections of Kras^G12D^-PDEC orthotopic lesions treated with tirabrutinib or vehicle control for 2 and 4 weeks as indicated. Representative images are shown. Mice pancreata were fixed, processed and stained by immunohistochemistry (IHC) as decribed previously ([@R7]). Antibody used was CK8 (1:200, TROMA-Ic, DSHB, University of Iowa; Iowa City, IA, USA). Slides were examined and imaged on a Nikon Eclipse 80i microscope. Scale bar, 200 μm. **b** graph depicts quantification of data from **a** indicating % CK8^+^ area within the lesion, determined using ImageJ software. (N=9, Vehicle, 2 weeks; N=9, tirabrutinib treament, 2 weeks; N=11, Vehicle, 4 weeks; N=10, tirabrutinib treatment, 4 weeks). Error bars indicate SD; *P*-value calculated using Student *t* test (two-tailed, unpaired). Data representative of two independent experiments. \*\*\*, P≤0.001, **c** IHC staining for phospho-Histone H3 (p-HH3) of Kras^G12D^-PDEC orthotopic lesions treated with tirabrutinib or vehicle control for 2 weeks. Representative images are shown. Antibody used was phospho-Histone H3 (1:200, 06--570, Millipore). Scale bars, 200 μm. **d** graph depicts quantification of data in **c** indicating percent positive p-HH3 staining in epithelial cells using ImageJ software (10 fields of view per animal; N=7). Error bars indicate SD; *P*-values determined by the Student *t* test (two-tailed, unpaired); \*\*\*\*, P≤0.0001. Data representative of two independent experiments.](nihms-1516906-f0004){#F4}
